Skip to main content
SNO 28th Annual Meeting Main banner
Final Program


Program
Icon Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
ISS CME
ISS CME
Named Award Winner
Named Award Winner
Award Winner
Award Winner
Poster Award Winner
Poster Award Winner

  1. Home

  • Friday, Nov 17th
    7:38 PM – 7:42 PM PT
    RTID-04 - GLUGLIO - A phase Ib/II randomized drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma (NCT05664464)
    Location: Exhibit Hall A/B
    Rapid and Poster Presenter: Hans-Georg Wirsching – University Hospital and University of Zurich
    Author: Patrick Roth – Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
    Author: Angela Fischer – Cantonal Hospital Chur
    Author: Andreas F. Hottinger – University Hospital of Lausanne
    Author: Thomas Hundsberger – Cantonal Hospital St. Gallen
    Author: Denis Migliorini – Universite de Geneve
    Author: Adrian Ochsenbein – Inselspital
    Author: Heinz Laeubli – University Hospital Basel
    Author: Katharina Seystahl – Cantonal Hospital Lucerne
    Author: Lukas Imbach – Swiss Epilepsy Centre
    Author: Tibor Hortobagyi – University Hospital and University of Zurich
    Author: Leonhard Held – University of Zurich
    Author: Andrea Bink – University Hospital and University of Zurich
    Author: Michael Weller – Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
    Randomized Trials in Development
  • Friday, Nov 17th
    7:42 PM – 7:46 PM PT
    RTID-05 - Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
    Location: Exhibit Hall A/B
    Rapid and Poster Presenter: Veronica Rendo – Uppsala University
    Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
    Author: Connor Bossi – Dana-Farber Cancer Institute
    Author: Nicholas Khuu – Dana-Farber Cancer Institute
    Author: Sangita Pal – Dana-Farber Cancer Institute
    Author: Abigail Reynolds – Dana-Farber Cancer Institute
    Author: Auriole Fassinou – Dana-Farber Cancer Institute
    Author: Keith L. Ligon – Brigham and Women's Hospital
    Author: Rameen Beroukhim – Center for Neuro-Oncology, Dana-Farber Cancer Institute
    Author: Patrick Y. Wen – Dana-Farber Cancer Institute
    Author: Michelle A. Rudek – Johns Hopkins University School of Medicine
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-01 - A randomized study of low-intensity focused ultrasound for blood-brain barrier disruption for brain metastasis from non-small cell lung cancer (LIMITLESS)
    Location: Exhibit Hall A/B
    Poster Presenter: Manmeet S. Ahluwalia – Miami Cancer Institute, Baptist Health South Florida
    Author: Michael W. McDermott – Miami Neuroscience Institute
    Author: Ahmad Ozair – Miami Cancer Institute, Baptist Health South Florida
    Author: Atulya Khosla – Miami Cancer Institute, Baptist Health South Florida
    Author: Arjun Sahgal – Sunnybrook Health Sciences Centre
    Author: Mark V V. Mishra – Maryland Proton Treatment Center
    Author: Achal Achrol – Insightec Inc.
    Author: K. Singh Sahni – Johnston Willis Hospital
    Author: Nader Sanai – Barrow Neurological Institute
    Author: Nir Lipsman – Sunnybrook Health Sciences Centre
    Author: Graeme F Woodworth – University of Maryland School of Medicine
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-02 - SILMET trial: a randomized, placebo-controlled study to evaluate SILibinin in preventing intracranial recurrence after complete resection of a single brain METastasis from NSCLC or breast cancer
    Location: Exhibit Hall A/B
    Poster Presenter: Alessia Pellerino – Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy
    Author: Andrea Pace – Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute
    Author: Filippo Flavio Angileri – Neurosurgery-Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina
    Author: Maria Caffo – Neurosurgery-Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina
    Author: Marco Gatti – Radiotherapy, Candiolo Cancer Institute - FPO, IRCCS
    Author: Alessandro Olivi – UOC Neurochirurgia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore
    Author: Quintino Giorgio D'Alessandris – UOC Neurochirurgia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore
    Author: Alessandra Fabi – Precision Medicine Breast Unit, Scientific Directorate, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Author: Luca Bertero – Pathology Unit, Department of Medical Sciences, University of Turin, Italy
    Author: Alessia Andrea Ricci – Pathology Unit, Department of Medical Sciences, University of Turin
    Author: Luca Mangherini – Pathology Unit, Department of Medical Sciences, University of Turin
    Author: Diego Garbossa – Division of Neurosurgery, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy
    Author: Neibla Priego – Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO)
    Author: Joaquim Bosch-Barrera – Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI); Department of Medical Sciences, Medical School, University of Girona
    Author: Manuel Valiente – Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO)
    Author: Riccardo Soffietti – University of Turin
    Author: Roberta Rudà – Division of Neuro-Oncology, Department of Neuroscience, University of Turin
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-03 - A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +- radiotherapy in adults with recurrent or newly diagnosed glioblastoma
    Location: Exhibit Hall A/B
    Poster Presenter: Patrick Roth – Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
    Author: Kyriakos P. Papadopoulos – START San Antonio, San Antonio, TX, USA
    Author: Maria Vieito – Hospital Universitari Vall d'Hebron
    Author: Jonathan T. Yang – University of Washington
    Author: Nazanin K. Majd – University of Texas MD Anderson Cancer Center
    Author: Juan M. Sepúlveda – Hospital Universitario 12 de Octubre
    Author: Lauren R. Schaff – Memorial Sloan Kettering Cancer Center
    Author: Victor Moreno – START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
    Author: Jaime Gállego Pérez -Larraya – Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain
    Author: Sandrine Micallef – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Anne Bellon – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Mokhtar Omar – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Esteban Rodrigo Imedio – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Luke Piggott – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Victor Rodriguez-Freixinos – Debiopharm International SA, Chemin Messidor 5-7, CP 5911, 1002 Lausanne, Switzerland
    Author: Jordi Rodon – Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-04 - GLUGLIO - A phase Ib/II randomized drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma (NCT05664464)
    Location: Exhibit Hall A/B
    Poster Presenter: Hans-Georg Wirsching – University Hospital and University of Zurich
    Author: Patrick Roth – Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
    Author: Angela Fischer – Cantonal Hospital Chur
    Author: Andreas F. Hottinger – University Hospital of Lausanne
    Author: Thomas Hundsberger – Cantonal Hospital St. Gallen
    Author: Denis Migliorini – Universite de Geneve
    Author: Adrian Ochsenbein – Inselspital
    Author: Heinz Laeubli – University Hospital Basel
    Author: Katharina Seystahl – Cantonal Hospital Lucerne
    Author: Lukas Imbach – Swiss Epilepsy Centre
    Author: Tibor Hortobagyi – University Hospital and University of Zurich
    Author: Leonhard Held – University of Zurich
    Author: Andrea Bink – University Hospital and University of Zurich
    Author: Michael Weller – Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-05 - Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
    Location: Exhibit Hall A/B
    Poster Presenter: Veronica Rendo – Uppsala University
    Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
    Author: Connor Bossi – Dana-Farber Cancer Institute
    Author: Nicholas Khuu – Dana-Farber Cancer Institute
    Author: Sangita Pal – Dana-Farber Cancer Institute
    Author: Abigail Reynolds – Dana-Farber Cancer Institute
    Author: Auriole Fassinou – Dana-Farber Cancer Institute
    Author: Keith L. Ligon – Brigham and Women's Hospital
    Author: Rameen Beroukhim – Center for Neuro-Oncology, Dana-Farber Cancer Institute
    Author: Patrick Y. Wen – Dana-Farber Cancer Institute
    Author: Michelle A. Rudek – Johns Hopkins University School of Medicine
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-06 - The pivotal METIS (EF-25) study of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) following radiosurgery
    Location: Exhibit Hall A/B
    Poster Presenter: Minesh P. Mehta – Miami Cancer Institute
    Author: Paul D. Brown – Mayo Clinic
    Author: Maciej Harat – Nicolaus Copernicus University
    Author: David Roberge – University of Montreal
    Author: Manmeet S. Ahluwalia – Miami Cancer Institute, Baptist Health South Florida
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-07 - A randomized window of opportunity trial with dose escalation to evaluate fluoxetine and temozolomide in glioma
    Location: Exhibit Hall A/B
    Author: Kirit Singh – Duke Brain Tumor Immunotherapy Program
    Poster Presenter: Chelsea Railton – Duke Brain Tumor Immunotherapy Program
    Author: Kelly M. Hotchkiss – Duke University
    Author: James E. Herndon, II – Duke Cancer Institute, Department of Biostatistics
    Author: Katherine B. Peters – Duke University Medical Center
    Author: Henry S. Friedman – The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
    Author: Annick Desjardins – Duke University
    Author: David M. Ashley – The Preston Robert Tisch Brain Tumor Center
    Author: Margaret O. O. Johnson – Duke University School of Medicine, The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
    Author: Anoop Patel – Department of Neurosurgery, Duke University
    Author: Allan H. Friedman – Department of Neurosurgery, Duke University
    Author: Michael Lim – Stanford University School of Medicine
    Author: Peter E. Fecci – Duke University Department of Neurosurgery
    Author: David Piccioni, MD, PhD – University of California San Diego Health
    Author: Tresa McGranahan – Scripps Cancer Center
    Author: Seema Nagpal – Division of Neuro-oncology, Stanford University
    Author: Erik P. Sulman – New York University Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
    Author: Paul S. Mischel – Stanford University
    Author: Mustafa Khasraw – Duke Cancer Institute
    Randomized Trials in Development
  • Friday, Nov 17th
    7:30 PM – 9:30 PM PT
    RTID-08 - A randomized, multicenter, double-blind, phase 2b study of IGV-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients
    Location: Exhibit Hall A/B
    Poster Presenter: Ian Y. Lee – Henry Ford Health
    Author: Kevin D. Judy – Thomas Jefferson University
    Author: Michael Schulder – Northwell Health at North Shore University Hospital
    Author: Simon Hanft – Westchester Medical Center
    Author: Linton T. Evans – Darmouth Hitchcock Medical Center
    Author: Julian Wu – Tufts University Medical Center
    Author: Sonikpreet Aulakh – West Virginia University
    Author: Eric T. Wong – Rhode Island Hospital
    Author: Vijay Agarwal – Montefiore Medical Center
    Author: Rohan Ramakrishna – Cornell University Weill Medical Center
    Author: J. Bradley B. Elder – Ohio State University
    Author: Brian J. Gill – Columbia University Medical Center
    Author: Alfredo Quiñones-Hinojosa – Mayo Clinic Florida
    Author: Cameron W. Brennan – Memorial Sloan Kettering Cancer Center
    Author: Raul Perez-Olle – Imvax, Inc.
    Author: Madhavi Diwanji – Imvax, Inc.
    Author: Gregory Pennock – Imvax, Inc.
    Author: Charles Scott – Imvax, Inc.
    Author: David W. Andrews – Imvax, Inc.
    Author: John A. Boockvar – Lenox Hill Hospital
    Randomized Trials in Development